Micropos Medical
Enabling accuracy in prostate cancer care
Micropos Medical is a Swedish medical device company that develops, manufactures, and sells technology enabling enhanced radiotherapy cancer treatment. Its product Raypilot® System, generates high precision as well as high efficiency through real-time tumour tracking in radiation treatment of prostate cancer. Raypilot is marketed in Europe and the US.
The Micropos Medical share is traded under the stock ticker MPOS on the Spotlight Stock Market.
For more information about the share, please visit Spotlight
Interim Reports
annual reports
Financial calendar
| DATE | EVENTS |
|---|---|
| 31 January 2024 | Interim report Q4/Year-end Report 2023 |
| 30 April 2024 | Interim report Q1 2024 |
| 31 July 2023 | Interim report Q2 2024 |
| 31 October 2024 | Interim report Q3 2024 |
| 30 January 2025 | Interim report Q4/Year-end Report 2024 |
For additional information, please contact:
Thomas Lindström, CEO, Micropos Medical AB (publ)
+46-31-760 80 05, info@micropos.se
-
news
New research: Five treatment sessions as effective as 39 for radiation therapy in prostate cancer
New research: Five treatment sessions as effective as 39 for radiation therapy in prostate cancer In mid-October, results were published from a British long-term follow-up study of 874 prostate cancer…
Sign up and get the latest news about Micropos Medical via Cision News
COMPANY INFO
LEARN MORE ABOUT OUR TEAM, BOARD AND OUR PRODUCTS
Follow us on LinkedIn
Let’s keep in touch